Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

Regeneron (REGN), a large-cap biotech stock, is part

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 407
Posts 54,283
Boards Moderated 29
Alias Born 12/16/01
160x600 placeholder
Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Sever... PR Newswire (US) - 3/30/2020 11:46:00 AM
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 PR Newswire (US) - 3/30/2020 12:59:00 AM
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program PR Newswire (US) - 3/17/2020 7:00:00 AM
Regeneron and Sanofi Start U.S. Studies Assessing Arthritis Drug As Coronavirus Treatment Dow Jones News - 3/16/2020 11:10:00 AM
Regeneron, Sanofi Start Trials for Drug to Treat Covid-19 Dow Jones News - 3/16/2020 8:57:00 AM
Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19 PR Newswire (US) - 3/16/2020 8:09:00 AM
Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19 PR Newswire (US) - 3/16/2020 8:00:00 AM
It's a Tough Time to Be in the C-Suite, Good Time to Be in a Gas Field Dow Jones News - 3/13/2020 7:29:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 5:00:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 4:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 4:06:26 PM
Regeneron, Sanofi to Test Arthritis Drug as Coronavirus Treatment -- 3rd Update Dow Jones News - 3/10/2020 7:27:00 PM
Regeneron, Sanofi to Test Arthritis Drug as Coronavirus Treatment -- 2nd Update Dow Jones News - 3/10/2020 6:24:00 PM
Biotech Stocks Stumble Despite Broad Market Rally Dow Jones News - 3/10/2020 6:21:00 PM
Regeneron, Sanofi to Test Arthritis Drug as Coronavirus Treatment -- Update Dow Jones News - 3/10/2020 6:00:00 PM
Only 29 Stocks in the S&P 500 Show Gains for the Past Month--Update Dow Jones News - 3/10/2020 5:26:00 PM
Only 19 Stocks in the S&P 500 Are in the Green for the Past Month Dow Jones News - 3/10/2020 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2020 4:06:43 PM
Regeneron Up Over 4%, on Pace for Highest Close Since September 2017 -- Data Talk Dow Jones News - 3/4/2020 12:29:00 PM
Regeneron Announces Upcoming Investor Conference Presentations PR Newswire (US) - 3/3/2020 4:05:00 PM
Correction to Health-Care Stocks Article Dow Jones News - 3/1/2020 4:28:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/28/2020 4:47:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/28/2020 4:46:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/28/2020 4:34:46 PM
Amid Steep Declines in Stocks, Investors Seek Winners in Health Care Dow Jones News - 2/28/2020 3:59:00 PM
TREND1 Member Level  Monday, 09/24/18 07:19:50 PM
Re: None
Post # of 141 
Regeneron (REGN), a large-cap biotech stock, is part of the Health Care SPDR (XLV) and a top ten holding in the Biotech iShares (IBB), Both ETFs hit 52-week highs recently and show upside leadership. The stock is lagging in the 52-week high category, but the long-term trend is up and the stock is breaking out of a flag formation.
First, the long-term trend is up because the stock broke the March highs with a 39% advance from May to August. Second, the 50-day EMA is above the 200-day EMA and price is above both EMAs.
After breaking the red resistance zone in early July, the stock established support in the 360 area over the last few months. Even after a gap down in early August, the stock held this support zone and moved above the early August high. The stock has since corrected with a falling flag of sorts and is edging above the trend line as I write (Monday morning, September 24th).


http://schrts.co/HscMEf


The indicator windows show upside volume increasing over the last few months and the PPO turning up. Note the advance began in mid May with a surge in upside volume and upside volume has largely outpaced downside volume the last four months. The PPO (5,30,5) flattened out just above the zero line and remains just below its signal line. A bullish signal line crossover would confirm the upturn on the price chart.



All my posts are just my opinions. I receive no compensation for
posts. These posts are for entertainment purposes only. I maybe
long or short or hold no position.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist